Since our inception, every milestone has pushed us to the next, enabling us to transform the future of eye care.
Our History
Our History of Firsts
1998
Glaukos is founded
1999
The first trabecular micro-bypass glaucoma stent is developed
2001
The first human implant of micro-bypass glaucoma stent is performed
2005
Landmark trial evaluating iStent® in conjunction with cataract surgery begins
2008
Glaukos receives Category III CPT code to describe insertion of a flow device into the trabecular meshwork of the eye
2012
Glaukos establishes a direct sales organization and launches iStent in the United States
2013
Glaukos secures 100% Medicare coverage for the iStent® procedure
2014
Glaukos establishes a direct sales organization and launches iStent inject®️️️️ in Germany
2015
Glaukos completes initial public offering
2016
iStent® is approved in Japan
iStent® launches in Australia and Canada
2017
Glaukos expands into 17 countries with direct sales operations
2018
iStent inject® is approved by the FDA in combination with cataract surgery; US commercial launch
2019
Glaukos acquires Avedro, establishing the cornerstone of a new corneal health franchise
Glaukos acquires DOSE Medical, establishing a new R&D retinal program
Glaukos enters licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform
2020
iStent inject® W is launched
The iLink® corneal cross-linking procedure is introduced to the Glaukos family
Glaukos completes convertible debt financing
Glaukos issues inaugural sustainability report
2021
Glaukos completes patient enrollment in Phase 3 clinical program for iDose TR
Glaukos surpasses 200 peer-reviewed publications on iStent technologies
Glaukos enters licensing agreement with Attillaps Holdings, Inc.
2022
U.S. commercial launch of iAccess, iPRIME, and iStent infinite®
Glaukos exceeds 1 million iStent devices implanted
Commenced Phase 2 clinical program for iLution platform
2023
Glaukos receives FDA Approval for iDose® TR (travoprost intracameral implant), 75 mcg
Glaukos commences first-in-human clinical development for retina program (GLK-401)
Looking Ahead
Glaukos is actively developing microsurgical devices, pharmaceuticals, and biosensors for the treatment of chronic eye disease. Stay tuned!
Empowering ophthalmic growth worldwide
With direct sales operations in 17 countries, we employ more than 250 commercial sales personnel worldwide. And we serve additional international markets through relationships with valued distributors. In all, our technologies are currently approved for use in more than 30 countries, and we continue to pursue regulatory approvals in more regions.